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CASE REPORT

Open Access

Rapid and sustained response to immune
checkpoint inhibition in cutaneous
squamous cell carcinoma after allogenic
hematopoietic cell transplant for sézary
syndrome
Karam Khaddour1,2 , Amy Musiek3, Lynn A. Cornelius3,4, Farrokh Dehdashti5,4, Peter Westervelt2,4,
Ryan Fields6,4 and George Ansstas1,4*

Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is not uncommon in association with indolent
malignancies that were treated with prior radiotherapy and after allogenic bone marrow transplantation. On the
other hand, cutaneous T-cell lymphoma (CTCL) is a subtype of non-Hodgkin’s lymphoma which is characterized by
an indolent course, with relative refractoriness to conventional chemotherapies and radiotherapy, and occasionally
referred for allogeneic hematopoietic cell transplantation (allo-HCT). Recently, the use of immune checkpoint
inhibitors has gained attention in the treatment of both cutaneous squamous cell carcinoma and hematological
malignancies. However, many patients with hematological malignancies eventually undergo allo-HCT, raising the
concern of potential adverse events (graft versus host disease) due to manipulation of the immune system with use
of checkpoint inhibitors.
Case presentation: We describe a patient with relapsed refractory CTCL (Sézary Syndrome) who underwent
allo-HCT with persistence of disease post-transplant. The patient additionally developed a progressively worsening
lesion on the right shoulder which was biopsied and showed poorly differentiated carcinoma (cSCC).
Pembrolizumab was started for the treatment of cSCC. After second cycle of treatment, the cSCC lesion responded
dramatically to the use of immune checkpoint inhibitor. Also, the patient experienced significant resolution of
pruritus and generalized erythema. During 24 months of follow up after initial treatment with checkpoint inhibition
immunotherapy, the patient showed durable response of both cSCC and CTCL, as well as restoration of full donor
chimerism, without obvious worsening of graft versus host disease (GVHD).
Conclusion: This is the first case to our knowledge of rapid and durable response of both cSCC and CTCL to
immune checkpoint inhibition after allo-HCT. Although this report highlights the potential for significant response
to this class of medication, further studies are required to confirm the efficacy and safety of this approach in
patients with CTCL after allo-HCT given the potential concern of GVHD.
Keywords: Cutaneous squamous cell carcinoma, Cutaneous T-cell lymphoma, Sézary syndrome, Immune
checkpoint inhibitors, Allogenic hematopoietic cell transplant, Pembrolizumab, Graft versus host disease
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Background
Conventional chemotherapies are considered not to be
curative in the majority of cutaneous T-cell lymphomas
(CTCL) [1]. Recently, the use of immune checkpoint inhibitors has largely expanded to include hematological
malignancies, specifically relapsed/refractory chemoresistant Hodgkin’s Lymphoma (r/r-cHL) and primary mediastinal large B-cell lymphoma [2, 3].The rationale relies
on the fact that genetic alterations occurring in the
microenvironment of lymphomas specifically in the programmed death ligand receptor (PD-L1/PD-L2) loci can
lead to overexpression of PD-L1/2 on malignant cells,
which helps tumor cells to evade the effective antitumor
immune response [4]. Similarly, CTCL such as Mycosis
Fungoides (MF) and Sézary Syndrome (SS) can debilitate
the immune response against malignant cells in the
tumor microenvironment and thus could be considered
a target for therapies that can restore immune surveillance [5]. However, there is a concern for the use of immune checkpoint inhibitors in patients with lymphoma
who undergo allogenic hematopoietic cell transplantation due to the possibility of triggering or aggravating
graft versus host disease. This has led to lack of literature regarding the safety and efficacy of immune checkpoint inhibitors in this population as patients with prior
history of allo-HCT were excluded from clinical trials
which examined the efficacy of immunotherapy. Moreover, advanced cutaneous squamous cell carcinoma has
been shown to have a high mutational burden which
could increase the expression of tumor neoantigens [6].
Also, the association with PD-L1 expression is established with cutaneous squamous cell carcinoma which
prompted the study of immune checkpoint inhibitors as
a potential therapy [7].
We describe the first case to our knowledge of a patient with a history of allo-HCT who had a rapid and
durable response of both cSCC and CTCL/SS after treatment with immune checkpoint inhibitors.
Case presentation
A 58-year-old Caucasian male with relapsed/refractory Sézary Syndrome (r/r SS) stage IVA was referred
for allogeneic hematopoietic cell transplantation (alloHCT). The patient had received multiple therapies prior
to being assessed for a transplant (Table 1). Positron
Emission Tomography/Computed Tomography (PET/
CT) with [18F]fluorodeoxyglucose (FDG) prior to transplant (1/17/2017) revealed interval development of a
new hypermetabolic soft tissue nodule in the skin of the
posterior right shoulder with maximum standard uptake
value (SUVmax) of 12.3 and a hypermetabolic right paratracheal lymph node (Fig. 1). Skin biopsy was consistent
with residual CTCL/SS, a bone marrow biopsy demonstrated hypocellularity with extensive involvement of
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Table 1 Sequence of systemic therapies administered since
diagnosis of cutaneous T-cell lymphoma/ Sézary Syndrome
Prior therapy for CTCL/
SS

Sequence and Duration

Photochemotherapy
(PUVA)

First Line of Therapy

8 months (2009)

Photopheresis

Second Line of
Therapy

31 months (2009–2012)

Romidepsin

Third Line of Therapy 48 months (2010–2014)

Pegylated liposomal
doxorubicin

Fourth Line of
Therapy

3 months (2014)

Gemcitabine

Fifth Line of Therapy

1 month (2014)

Alemtuzumab

Sixth Line of Therapy

2 months (2015)

Mogamulizumab

Seventh Line of
Therapy

1 month (2015)

Total skin electron
beam therapy

Eighth Line of
Therapy

3 months (2016)

Bexarotene

Ninth Line of Therapy 2 months (2016)

Pralatrexate

Tenth Line of
Therapy

2 months (2016)

ICE (Ifosfamide,
Carboplatin, Etoposide)

Eleventh Line of
Therapy

3 months (2016–2017)

Sibling allogenic stem
cell transplantation

Twelfth Line of
Therapy

(2017)

mature T-cell lymphoma (79% by flow cytometry), and
cytogenetic studies revealed no aberrations. The patient
underwent allogeneic hematopoietic cell transplantation
(allo-HCT) using a fully matched male sibling donor.
The myeloablative conditioning regimen prior to transplant consisted of hyperfractionated total body irradiation combined with high dose cyclophosphamide. Graft
versus host disease (GVHD) prophylaxis consisted of
tacrolimus and methotrexate. Tacrolimus was subsequently changed to sirolimus due to peri-transplant
neurotoxicity. Shortly after transplantation (week 7), the
patient developed a diffuse erythematous rash, a biopsy
of which was most consistent with skin GVHD (vs
CTCL vs drug rash) and received prednisone, mycophenolate mofetil (MMF) with ongoing sirolimus with
improvement, and subsequent tapering to low dose
prednisone (5 mg daily/ week 23). A bone marrow biopsy 4 months after allo-HCT showed persistent marrow (and peripheral blood) involvement with sézary cells
(15% bone marrow involvement by mature T-cell lymphoma with CD4+/CD8+ ratio > 100). There was also
mixed chimerism by short tandem repeat (STR) assay
with 82% donor cells (Fig. 2). There was incomplete
resolution of the skin manifestations of CTCL, which included generalized erythema and pruritus. Repeated skin
biopsies were consistent with residual CTCL/SS. Five
months after allo-HCT, STR studies again demonstrated
persistent mixed chimerism, and donor lymphocyte infusions (DLI) in two separate doses were administered on

J Immunother Cancer: first published as 10.1186/s40425-019-0801-z on 4 December 2019. Downloaded from http://jitc.bmj.com/ on September 1, 2022 at Washington University School of
Medicine Library &. Protected by copyright.

Khaddour et al. Journal for ImmunoTherapy of Cancer

a.

(2019) 7:338

b.

Page 3 of 7

c.

Fig. 1 Anterior and posterior volume-rendered maximum activity-reprojection FDG-PET images showing (a) FDG uptake in the right shoulder
(arrow) and a paratracheal lymph node. b markedly hypermetabolic lesion in the right shoulder with SUVmax of 26.7 (arrow), markedly
hypermetabolic right axillary and right paratracheal lymphadenopathy with SUVmax of 27.3 with interval development of hypermetabolic focal
cutaneous lesions, left axillary lymph node and pulmonary lesions. c near complete response of the right shoulder hypermetabolic lesion (arrow),
complete resolution of paratracheal lymph node, left axillary lymph node, pulmonary and cutaneous lesions, with persistent FDG uptake of the
right axillary lymph nodes

weeks 26 and 31 (1 and 3 X 10e7 CD3 cells/kg, respectively) without complete resolution of skin symptoms or
erythema. Following allo-HCT, there was a gradual
worsening of a right shoulder skin lesion noted on PET/
CT prior to transplant, and thought to be related to mycosis fungoides secondary to CTCL. The skin mass eventually extended over the superior aspect of the right
shoulder with ulceration and hard induration, and 3
months post allo-HCT, the patient underwent subsequent involved-field radiotherapy with a total dose of 50
Gy. The lesion persisted and grew to 17 × 10 cm in maximum dimension with worsening necrosis, ulceration,

and spread to the anterior chest wall (Fig. 3), a skin biopsy was performed and histopathology revealed poorly
differentiated squamous cell carcinoma. Magnetic Resonance Imaging (MRI) of the shoulder showed a right
lesion with no bone or muscular invasion, but there was
extensive right axillary lymphadenopathy. FDG-PET/CT
revealed worsening of disease with extensive markedly
hypermetabolic soft tissue thickening in the right shoulder with SUVmax of 26.7 and interval development of
markedly hypermetabolic partially necrotic right axillary
lymphadenopathy with SUVmax of 27.3, as well as worsening in FDG uptake of the right paratracheal lymph

Fig. 2 Timeline of bone marrow chimerism performed with STR studies after bone marrow transplantation. * Donor lymphocyte infusion was
administered on two separate doses on weeks 26 and 31. Pembrolizumab cycle 1 was at week 36 and last cycle (cycle 14) was at week 78
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Fig. 3 Skin lesions of CTCL and cSCC before and after PD-1 inhibition. a: Generalized eruption of small confluent erythematous macules and
papules on the anterior chest wall after stem cell transplant and before pembrolizumab. b: resolution of the previously mentioned erythematous
maculopapular eruption after pembrolizumab. c: multiple firm nodules with partial ulceration and keratin deposition on the superior aspect of the
right shoulder representing poorly differentiated squamous cell carcinoma (before pembrolizumab), also erythematous eruption can be noted
around the cSCC lesion which represents cutaneous lymphoma. d & e: Granular tissue with skin regeneration replacing the nodular ulcerated
lesions of cSCC (after pembrolizumab), there is complete resolution of the papular erythematous rash. CTCL: cutaneous T cell lymphoma, cSCC:
cutaneous squamous cell carcinoma

node. There was interval development of hypermetabolic
focal cutaneous lesions, left axillary lymph nodes and
pulmonary lesions (T3N2B; Stage IV SCC) (Fig. 1).
After discussion of treatment options with the patient,
intravenous pembrolizumab was started at a dose of 200 mg
every 3 weeks. The patient had an Eastern Cooperative Oncology Group performance of (ECOG 3) prior to beginning
of treatment. After 2nd cycle of pembrolizumab, a macular
rash appeared on the lower back. Skin biopsy demonstrated
superficial perivascular mixed inflammatory cell infiltrate
with normal CD4+/CD8+ ratio and was consistent with
grade I skin immune related adverse event (IRAEs) due to
pembrolizumab. Prednisone 60 mg was started and tapered
over a total of 4 weeks with complete resolution of the skin
symptoms secondary to IRAEs. The cutaneous manifestations including generalized erythema and pruritus which

were secondary to CTCL resolved completely after the 2nd
cycle of immunotherapy. A FDG-PET/CT after the 5th cycle
of pembrolizumab showed marked metabolic response and
near-complete resolution of the superficial right shoulder
mass (SUVmax of 1.9), and complete resolution of right paratracheal and left axillary lymph nodes, as well as pulmonary
and cutaneous lesions. There was decreased but persistent
FDG uptake in the necrotic right axillary lymph nodes
(SUVmax of 18.2) (Fig. 1). Given the rapid and significant response, pembrolizumab was continued for another three cycles and repeated PET/CT showed continued response with
decreased FDG avidity in the right axilla. After cycle 14, the
patient underwent right axillary lymph node dissection
encompassing levels 1–3 nodes for assessment of the
residual persistent lymphadenopathy on the right side.
Histopathology demonstrated metastatic squamous cell
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carcinoma in 3 of 17 lymph nodes. His post-operative
course was uncomplicated. The complete course of pembrolizumab treatment consisted of 14 cycles, over a course
of 9 months. Follow up 24 months after initiation of
immune checkpoint blockade therapy (14 months after
stopping pembrolizumab) revealed no evidence of recurrence of cSCC. There was no compelling evidence
of either progression of CTCL/SS or a flare in GVHD
throughout his course of checkpoint inhibition therapy (most recent peripheral blood flow cytometry on
week 120 showing no morphologic or immunophenotypic evidence of atypical lymphocytosis or sézary
cells and CD4+/CD8+ ration of 0.65).

Discussion
Systemic treatment of locally advanced and metastatic
cutaneous squamous cell carcinoma has been limited
with the exception of recent data supporting the potential role of immune checkpoint blockade specifically
cemiplimab [8] among other ongoing trials with other
PD-1 and PD-L1 inhibitors (Clinical Trials.gov. Identifiers: NCT02978625, NCT02964559, NCT03284424 and
NCT03108131). Also, the data supporting the use of immune checkpoint inhibitors in the treatment of
hematological malignancies other than classical Hodgkin’s Lymphoma (cHL) or primary mediastinal large Bcell lymphoma is limited. A new incentive of implementing immune checkpoint blockade in the treatment of Tcell lymphomas is supported by preclinical studies that
showed programmed cell death ligand-1 (PD-L1) receptors to be expressed on malignant cells which contribute
to suppression of host immunity against the malignant
cells. This leads to overgrowth in T-cell clones derived
from non-Hodgkin lymphoma [9]. Our case demonstrates a rapid and durable response after treatment with
immune checkpoint inhibitors manifested by a resolution of CTCL/SS symptoms within 6 weeks and a remission period of 24 months since initiation of a PD-1
inhibitor. The indication to use pembrolizumab in our
patient was for the treatment of poorly differentiated cutaneous squamous cell carcinoma. The theoretical possibility of a derived benefit against CTCL/SS was taken
into consideration when starting treatment. Also, the
possibility of exacerbating GVHD was also considered.
Both poorly differentiated cutaneous squamous cell carcinoma (cSCC) and CTCL/SS responded rapidly within
6 weeks (2 cycles) after initiation of PD-1 inhibitor, without an evidence of GVHD flare.
Early phase clinical trials using the PD-1 inhibitor (nivolumab) in refractory/relapsed cutaneous T-cell lymphomas demonstrated different objective response rates
(ORR) ranging from 15% in mycosis fungoides (MF) to
40% in peripheral T-cell lymphoma/Sézary Syndrome (SS)
in phase I studies (number of evaluable patients = 18) [10].
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However, the previous study excluded patients with prior
allogenic hematopoietic cell transplant. A different
study using pembrolizumab demonstrated an ORR of 38%
in 24 evaluable patients with MF/SS stages Ib-IV with the
longest duration of response reported to be 46 weeks [11].
Interestingly, there were higher response rates in retrospective studies examining the role of PD-1 inhibition
after allo-HCT compared to patients who received immunotherapy prior to transplant for r/r-cHL [12, 13].
These two previous retrospective studies showed ORR of
95 and 77% with 1 –year progression free survival (PFS) of
85.2% compared to ORR of 75 and 87% respectively in patients who received immune checkpoint inhibitors prior
to transplant [2, 12–14]. This raises the hypothesis that
immune checkpoint blockade could have a synergistic role
after allo-HCT or a role in homing of donor T-cells leading to an enhanced graft versus tumor effect. Some data
support the previous hypothesis as immune escape is one
of the mechanisms considered to cause relapse after transplant in hematological malignancies, and T-cell exhaustion is a potential mechanism of relapse after allo-HCT
due to overexpression of PD-1/PD-L1 receptors, which
leads to inactivation of effective T-cells in the tumor
microenvironment [15]. Norde et al. found that relapsed
myeloid leukemia after allo-HCT had higher expression
and upregulation of PD-L1 receptors on progenitor malignant clones. It was also observed in the same study the
suppressive effect on allogenic CD3+ T-cells when there
was high expression of PD-L1 on malignant leukemic
cells. Interestingly, blockade of the PD-1/PD-L1 interaction can augment the expansion of effector CD8+ Tcells and reactivate unresponsive T-memory cells in the
microenvironment required for graft versus leukemia effect [15]. Moreover, there is a small body of evidence supporting a role of immune checkpoint inhibitors in the
bone marrow microenvironment in acute myeloid
leukemia (AML), myelodysplastic syndrome (MDS) and
myelopthisis due to melanoma [16, 17].
The concern with the use of immune checkpoint inhibitors after allo-HCT is the development of graft versus host
disease (GVHD). Conflicting data exist regarding the occurrence of this adverse event, with some studies reporting
increased incidence and worsening of preexisting GVHD
with 30% (6 of 20 patients), and 26% deaths in patients
who received immune checkpoint blockade after allo-HCT
[12, 13]. In the previous two retrospective studies there
were 10 deaths related to GVHD in 51 patients (23 of
whom developed GVHD) [12, 13]. However, another retrospective study assessing patients who were treated with immune checkpoint inhibitors after allo-HCT did not report
GVHD development in any of the 7 evaluable patients [18].
The largest systematic review assessing the risk of
GVHD with immune checkpoint inhibitors after alloHCT showed that 49% of patients who developed
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GVHD had a prior history of the disease [19]. Some of
the predictive factors of GVHD development in this patient population were higher doses of immune checkpoint inhibitors, shorter intervals between transplant
and start of immunotherapy, and previous history of
GVHD. This systematic review also supports other observations of higher response rates when immune checkpoint inhibitors were administered after transplant
compared to those who received immunotherapy before
they underwent allo-HCT [12, 13, 19].
In our case, we did not observe GVHD after treatment
with PD-1 inhibitors. In fact, the patient’s erythema and
pruritus which were manifestations of patient’s CTCL
improved significantly after starting pembrolizumab.
Moreover, there was a dermatological immune related
adverse event observed in the patient during treatment
(after 2nd cycle of pembrolizumab) which correlated
with the response of both cSCC and CTCL. The previous observation is supported by a retrospective study
showing robust immune response to PD-1/PD-L1 inhibitors when lichenoid and spongiotic IRAEs develop during treatment with PD-1/PD-L1 inhibitors [20].
It should be noted that donor lymphocyte infusion
(DLI) which was performed in our patient on weeks 26
and 31 could have potentially led to full engraftment of
allo-HCT resulting in the response observed in CTCL.
The median response from administration of DLI to full
engraftment is estimated to be 8–12 weeks [21]. However, the response of cSCC and CTCL in our case was
observed to occur only after the administration of pembrolizumab (first cycle was at week 36) and the substantial deep response was observed after the second cycle
which was at week 39.
In conclusion, our case is the first to describe a rapid
and sustained clinical response of both CTCL/SS and
cSCC to immune checkpoint inhibition after allo-HCT,
without development of GVHD. However, this observation should be interpreted with caution given the nontrivial concern of GVHD. Further larger studies are
needed to confirm the efficacy of immune checkpoint
inhibitors and their safety profile in this patient
population.
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